Delivery Order SPE2DB20D2104-SPE2DB25FMZPU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,748.58 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count units) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Eliquis 5 mg tablets in quantities of 60 units, with a ceiling value of $9,366.47. This competitive, firm fixed-price delivery order is expected to be completed by August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,719.90 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 2.5 mg on July 24, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a firm fixed price delivery order valued at $7,091.61 for 60 tablets of Eliquis 5 mg, a commonly prescribed anticoagulant medication. The award, issued on September 5, 2025, with an ultimate completion date of September 8, 2025, represents a non-set-aside competitive award. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- AmerisourceBergen Drug Corp was awarded a delivery order on September 9, 2025, by the Defense Logistics Agency to supply 60 tablets of Eliquis 5 mg for $12,352.75, with final delivery required by September 10, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the vendor's substantial pharmaceutical supply relationship with the federal government. The order was fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $14,034.53 delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a $2,896.47 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg on June 3, 2025, with completion expected by June 4, 2025. This is a firm fixed-price, non-set-aside contract that will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999,999,999.00 global...
- The Defense Logistics Agency awarded a delivery order valued at $8,024.06 to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg on September 25, 2025, with completion scheduled for September 26, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract involves no...
- The Defense Logistics Agency awarded a delivery order valued at $8,887.80 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) on September 2, 2025, with an ultimate completion date of September 3, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $17,742.12 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitive award utilizes firm fixed pricing and carries no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a prime contractor under the agency's pharmaceutical supply chain and fulfills this order from its corporate office location. This...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMZPUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,592.51 to AmerisourceBergen Drug Corp for 60 tablets of Eliquis 5 mg on September 4, 2025, with a completion date of September 5, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal military and veteran healthcare systems. This delivery order for Eliquis, an anticoagulant medication, reflects the company's comprehensive role in supplying brand-name and generic pharmaceuticals to support military healthcare programs globally. The award demonstrates AmerisourceBergen's continued capability to meet federal procurement requirements through open competition and its established position as a primary pharmaceutical supplier within the DLA's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.6k | 9/4/25 |